Acute glaucoma is an inflammatory disease

Article

Acute glaucoma in mice is largely an inflammatory disease, and high intraocular pressure (IOP) causes vision loss by starting an inflammatory response similar to that caused by bacterial infections.

Acute glaucoma in mice is largely an inflammatory disease, and high intraocular pressure (IOP) causes vision loss by starting an inflammatory response similar to that caused by bacterial infections. That's according to researchers at the University of California, San Diego (UCSD) School of Medicine and Sun Yat-sen University in China.

"Our research is the first to show an inflammatory mechanism by which high ocular pressure causes vision loss in acute glaucoma patients," said co-senior author Professor Kang Zhang, MD, PhD, a professor of ophthalmology at UCSD.

The findings were published in the Proceedings of the National Academy of Sciences.

In the study, the investigators showed that a rapid, sustained large increase in IOP in mice turns on the TLR4 gene, which activates a protein, caspase-8. This signalling protein, in turn, triggers the production of inflammatory proteins that normally help mammals fight microbial infections.

"This immune response is a double-edge sword because, while these proteins protect us from infection in a normal situation, they stimulate apoptosis in retinal cells in cases of acute glaucoma," said Prof. Zhang, who is also a staff physician at the Veterans Affairs San Diego Healthcare System.

To further confirm the mechanism linking high IOP to retinal damage, the researchers showed that they could slow retinal cell death in mice with acute glaucoma by suppressing either the TLR4 gene or caspace-8 protein. The latter is particularly significant because caspace-8 inhibitors are being tested in clinical trials of potential cancer and stroke treatments.

"By injecting these inhibitors into the eyes of acute glaucoma patients, it may be possible to evaluate and bring them vision-sparing treatments more quickly," said paper co-author Professor Robert N. Weinreb, MD, chairman and Distinguished Professor of Ophthalmology at UCSD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.